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Additionally, variables such as performance status [12],Introduction
weight loss, time to progression, number and type of
metastases [13], vascular invasion [14] and severalPrognostic markers include factors measurable in serum
or tissue specimens using an assay; quantitative or laboratory values, e.g. haemoglobin level, ESR and alka-
line phosphatase levels, have been studied in relation toqualitative changes from a defined baseline level are
correlated with prognosis. Ideally, a prognostic marker prognosis [13]. Increasing knowledge of cytogenetic
abnormalities and the role of oncogenes and tumourshould have high specificity, sensitivity and reproduc-
ibility. It should be organ- and cancer-specific, and have suppressor genes in RCC is critical, but the study of
molecular mechanisms underlying RCC is still in itsthe power to predict the prognosis. Furthermore, its
assessment should be practical, easy and cost-eCective. infancy; future studies will have to provide information
on the implications for the prognosis of patients withA prognostic marker should be useful in patient manage-
ment and clinical-decision making, resulting in improved RCC.
clinical outcome.
However, the ideal prognostic marker has not been
Stage
discovered for any of the urological malignancies. Few
markers are routinely used in clinical decision-making The TNM system, which explicitly defines the anatomical
extent of disease, is the most commonly used stagingor have been studied in clinical trials. In this review, we
discuss the clinical use of tissue-related prognostic factors system. Several studies have shown that stage is the
most consistent single prognostic factor to influencein RCC and bladder cancer, and review the published
literature on experimental prognostic markers. survival [5–8,15]. Survival is inversely correlated with
pathological stage as patients with tumours confined to
the kidney have significantly better disease-specific sur-
Renal cell cancer
vival rates than patients with metastatic RCC [16]. The
significance of invasion into the renal vein, vena cava,Radical surgical extirpation of a kidney tumour remains
the only eCective means of curing localized RCC, despite renal pelvis, perinephric fat and lymph nodes has been
the subject of much debate [12]. Most studies do notalternative forms of therapy which have been proposed
over the last decade. Patients with metastatic RCC have regard renal vein invasion as a factor that reduces
survival [6,9,17]. Tumour penetration into the renala poor prognosis, with a median survival of approxi-
mately 8 months [1] and limited therapeutic options; pelvis was thought to reflect tumour stage rather than
biological behaviour and is therefore not an independentRCC is resistant to most conventional cytotoxic agents
[2]. More recently, the use of biological response modi- prognosticator [16]. Data addressing the issue of inferior
vena cava invasion are conflicting. Several large seriesfiers, especially IL-2 and IFNa, has lead to some responses
in patients with metastatic disease [3,4]. found that invasion of the vena cava minimally aCected
survival, as long as the tumour thrombus could beThe clinical course of metastatic RCC is variable. To
obtain an insight into the clinical and biological behav- totally removed [18,19]. Patients with RCC invading the
renal capsule and perinephric fat have a worse survivaliour of RCC the identification of new prognostic factors
is vital. Eventually, the use of these factors should than those with organ-confined disease [20,21]. Lymph
node invasion is an ominous prognostic sign and has afacilitate the choice of optimal treatment for individual
patients. Investigators have attempted to identify patho- significant impact on survival [9,22]. From these retro-
spective studies it is uncertain if patients with positivelogical and morphological features within the tumour
that correlate with survival in patients with RCC. lymph nodes would benefit from lymph node dissection.
Whether extended lymphadenectomy improves the sur-Tumour stage remains the most important factor predic-
tive of survival in RCC [5–8]. In addition, tumour size vival of patients with RCC may be answered by the
ongoing EORTC 30881 randomized trial. Patients with[7], histological pattern [9], cell type [9], nuclear grade
[7], DNA content [10] and nuclear morphometry [11] metastatic RCC have a poor prognosis, with 5- and
10-year survival rates of 5–10% and 0–7%, respectively.have been reported as prognosticators for survival.
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Despite great eCort to challenge metastatic disease with tumours being associated with a less favourable outcome.
However, most studies did not account for tumour stage,adjuvant treatments, the overall survival of patients has
not been improved. Survival probably depends on the histological grade or tumour heterogeneity, and there
were too few patients in these studies to draw definitebiological aggressiveness of the tumour and not on the
site(s) of metastatic lesions, although pulmonary metast- conclusions about this potential prognosticator.
ases appear to be associated with a better prognosis. In
selected cases, excision of solitary lesions may improve
Cytogenetic findings
the duration of overall survival [23]. In retrospective
analyses, nephrectomy in patients with systemic disease Cytogenetic analysis has shown a close correlation
between certain recurrent chromosomal rearrangementsdid not alter the subsequent disease course [17]. Only a
select group of patients who were relatively more suitable and several RCC subtypes [32]. Clear cell carcinomas
have deletions or translocations involving the short armto undergo surgery and had a few surgically resectable
metastases may have benefited from nephrectomy with of chromosome 3, with breakpoints proximal to 3p22.
Papillary tumours have allelic losses of 17p or trisomiesextirpation of metastatic lesions. With the development
of modern immunotherapy, this issue needs to be of chromosomes 7, 16 and/or 17. Chromophobic cell
carcinomas have hypodiploid chromosome numbers,re-addressed. In an EORTC study (protocol 30947)
patients with metastatic RCC are randomized to either oncocytomas have deletions (−Y and −1) and collecting
duct carcinomas have been characterized by deletionsimmunotherapy alone or tumour nephrectomy followed
by immunotherapy. This important study should shed −1, −6, −14, −15 and −22. Some tumours with
predominantly papillary/chromophilic histology andfurther light on the role of nephrectomy in metastatic
RCC and may well change current attitudes towards translocations in Xp11.2 have been reported [33]. It has
been suggested that RCC may be subdivided into diCerenthow we treat this condition.
groups based on genetic abnormalities and that these
cytogenetic aberrations may be of prognostic importance
Grade
[33,34]. Other authors found no correlation between
cytogenetic changes and prognosis [35–37]. In a recentThe grading of RCC has proved to be diBcult; Skinner
et al. [6] and Fuhrman et al. [24] developed grading study, Elfving et al. [32] evaluated the prognostic impact
of cytogenetic findings in RCC in 50 patients. Patientssystems based on nuclear morphometry of RCC cells.
Several studies reported the independent prognostic with more than five cytogenetic findings had a signifi-
cantly worse prognosis than patients with fewer changes.value of grade in predicting long-term survival
[6,17,24,25]. Tumour cell type (i.e. clear granular, Patients with deletions (8p)/−8,+12 and +20 had a
significantly worse prognosis. However, grade was thespindle or mixed) also appears to influence survival.
Tumours with spindle cells are significantly more malig- most reliable independent prognosticator for recurrent
disease in this study. Further studies, involving morenant than the other cell types [6,26]. Although nuclear
grade is an independent prognosticator, it is usually only patients, are needed to evaluate the implications of
karyotypic changes in RCC.second to stage in significance, as lack of uniformity and
inherent subjectivity of grading systems have prevented
their widespread application.
Vascular invasion
In a recent study, the correlation between microscopic
Nuclear morphometry
vascular tumour invasion and disease-free interval after
surgery for RCC was examined [14]. Compared withMorphometric analysis of renal carcinoma cells appears
to predict survival, as shown in several studies [27–29]. classical tumour stage, grade and tumour diameter,
microvascular invasion was found to be the single mostIn one study, the 5-year survival rates were significantly
poorer if the nuclear area was >35 mm2 [27]. Further relevant prognosticator after presumed curative radical
nephrectomy for RCC. In patients undergoing radicalstudies are necessary with larger groups of patients to
confirm the value of nuclear morphometry as a prognos- nephrectomy for clinically nonmetastatic RCC with mic-
rovascular invasion but without lymph node involve-tic factor.
ment or macroscopic vascular invasion, the chance of
disease progression was estimated at 45% within one
DNA content
year.
Several groups have reported that tumour DNA content
as measured by flow cytometry may have prognostic
value in patients with RCC [10,30,31], with aneuploid
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detection methods are being developed in an attempt to
Clinical and laboratory variables
identify and monitor those patients with noninvasive
bladder cancer who are at risk of developing recurrentThe overall survival rate among young adults with RCC
is similar to that of older patients [38] and hence age or progressive disease. Patients with muscle-invasive
disease may benefit from the use of markers that predictdoes not appear to have prognostic significance. The
adverse impact of male gender in RCC has been suggested a tumour’s metastatic potential and the outcome of
therapy. We will discuss the available prognostic mark-[38] but several large studies, using multivariate analy-
sis, did not confirm male sex as a prognostic factor ers, of which relatively few have confirmed clinical
utility. Nevertheless, in the near future, the increased[17,39]. Most diCerences in survival between the sexes
are related to diCerences in stage and grade of tumours. use of new prognostic factors may modify the way we
manage patients with TCC of the bladder.Several authors have reported the prognostic import-
ance of diCerent signs and symptoms. Weight loss
[17,26,38,40,41] and performance status [13,40] are
Stage
important, but are also associated with advanced stages.
Various laboratory results may be adversely related to The selection of initial therapy currently depends on
clinicopathological variables. Tumour stage, reflectingprognosis. Using univariate analysis, Citterio et al. [13]
reported that anaemia at diagnosis predicted a poor depth of invasion, remains the most common prognosti-
cator for progression. Several studies have shown thatoutcome of metastatic RCC, as well as hypercalcaemia,
hypoalbuminaemia and high serum alkaline phospha- the risk for progression is significantly greater in T1
than Ta tumours [44].tase. The ESR has also been related to a poor prognosis
[42]. Serum levels of erythropoietin correlate with
tumour stage and grade, and may provide prognostic
Grade
information [43].
The grading system involves three classes and is based
on the degree of anaplasia. Several studies have shownConclusion
the power of grade in predicting muscle invasion [45].
Identification and use of prognostic factors will become
increasingly important in defining subgroups of patients
DNA ploidy
with RCC who have a poor prognosis. This will allow
better selection and evaluation of treatment, leading to An increase in nuclear DNA content is regarded as a
sign of genetic instability associated with potential malig-improved management of patients with RCC and of the
design and analysis of clinical trials in RCC. nant behaviour. DNA ploidy in cells obtained from
bladder washings was correlated with progression to
invasion and metastasis, and poor prognosis in flowBladder cancer
cytometric studies [46,47]. However, it is questionable
whether ploidy provides additional information toTCC of the bladder can be classified into two groups with
distinct behaviour and prognosis; low-grade tumours tumour grade and stage [11,48]. Cellular DNA content
may be of prognostic value only in grade 2 TCC, as most(papillary and usually noninvasive) and high-grade
tumours (papillary or nonpapillary and often invasive). grade 1 tumours are diploid and most grade 3 tumours
are aneuploid [49].TCC of the bladder consists of noninvasive tumours (Ta,
Tis and T1) for 75–85% of patients and invasive (T2, Sto¨ckle et al. [50] using paraBn-embedded bladder
carcinoma tissue from radical cystectomy, found that inT3, T4) or metastatic tumours in 15–25%. Of the
patients with noninvasive bladder cancer, >70% will case of noninvasive tumours, DNA cytometry identified
potentially invasive tumours. Monosomy of chromo-have one or more recurrences after initial treatment and
in a third progressive disease will develop. Primary somes 13 and 22 was correlated with a poor prognosis
and trisomy of chromosomes 7 with a favourable prog-therapy is based on clinical staging and morphological
assessment. However, tumours may behave diCerently nosis [51]. However, bladder cancers consist of cell
populations heterogeneous in ploidy. A ‘non-tetraploid’despite morphological similarity. It is of great importance
to identify patients with noninvasive tumours who are DNA aneuploidy in a bladder washing specimen is
considered to be recurrent tumour in patients withlikely to develop recurrent or progressive disease; tumour
markers may contribute to this goal. Recent develop- noninvasive bladder cancer treated by TUR. DNA aneu-
ploidy  6 months after intravesical treatment of non-ments in molecular and genetic techniques have contrib-
uted to our understanding of bladder cancer tumour invasive tumours is a good prognosticator for treatment
failure and progression [49]. The prognostic value ofbiology. Biological markers and new bladder cancer
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DNA ploidy in muscle-invasive TCC remains debatable. had a significantly higher recurrence rate and lower
survival rate than cases with moderate Rb expressionThe routine use of flow cytometry and image analysis of
morphonuclear variables requires further clinical studies [61]. In the same study, patients with tumours showing
both altered p53 and Rb expression had significantlyand standardization of techniques.
increased rates of recurrence and decreased survival.
The authors concluded that bladder tumours highly
P53 tumour suppressor gene
expressing Rb showed no tumour-suppressor eCects of
the protein and that alterations in both p53 and Rb mayThe tumour suppressor gene p53 is located on chromo-
some 17p13–1 and codes for a 53-kDa nuclear phospho- act together or synergistically to promote tumour
progression.protein. The role of p53 is critical to cell cycle control,
resulting in cell cycle arrest to allow DNA repair or
induction of apoptosis in the event of irreparable DNA
E-cadherin
damage. Inactivation of p53 by deletion and/or mutation
results in loss of tumour suppressive function. Bladder Decreased expression of E-cadherin may play a role in
tumour invasion and metastasis, as E-cadherin-mediatedcancer, especially of the invasive type, is associated with
a high frequency of p53 mutations. Several immuno- cell-cell adhesion appears to play a critical role in
epithelial integrity [62]. Loss of E-cadherin expressionhistochemical studies have confirmed that altered
expression of the protein product(s) of mutated p53 is may be an important prognostic factor. Decreased
E-cadherin immunoreactivity was shown to correlateassociated with tumour progression in patients with T1
bladder cancer [52,53]. Patients with p53-positive with both increased grade, stage and poor prognosis in
patients with bladder tumours [63–65]. Another studynuclear staining had a significantly shorter disease-free
interval. The frequency of p53 mutations may thus reported an inverse relation between recurrence-free
survival and E-cadherin expression in bladder cancerpredict clinical aggressiveness. In contrast, a further
study, this time of invasive tumours, applying PCR-SSCP biopsies [66]. Using multivariate analysis, E-cadherin
expression had no independent prognostic significanceto assess the mutational status of p53, found no signifi-
cant association with survival [54]. This may reflect the over grade and stage. Otto et al. [67] showed that down-
regulation of E-cadherin in association with an increasediscrepancy between p53 mutation analysis and p53
immunohistochemistry. In another study of patients with in gp78, an autocrine motility factor receptor, was
associated with a poor prognosis. The combined appli-TCC confined to the bladder, an accumulation of p53 in
the tumour-cell nuclei predicted a significantly increased cation of these two antigens may identify patients
with high-risk bladder cancer and influence treatmentrisk of recurrence and death, independently of tumour
grade, stage and lymph-node status [55]. In two recent decisions.
studies, p53 nuclear reactivity did not indicate the
outcome of chemotherapy for metastatic disease [56,57].
Epidermal growth factor receptor (EGFR)
Large prospective studies are needed to evaluate the
nuclear overexpression of p53 protein as a prognostic An immunohistochemical study in patients with nonin-
vasive TCC (pTa, pT1) showed that overexpression ofmarker in bladder cancer.
EGFR, the product of the c-erbB-1 gene, was correlated
with a significantly higher recurrence rate, shorter time
Retinoblastoma gene
to recurrence and higher tumour progression [68].
EGFR-positive patients with muscle-invasive diseaseLoss of heterozygosity at chromosome 13q14, the site of
the retinoblastoma (Rb) gene, occurs in bladder cancer showed no diCerence in survival.
Overexpression of the c-erbB-2 gene product, a trans-with a wide range of incidence [58]. Rb is a tumour-
suppressor gene whose protein product has a function membrane growth factor receptor with significant
sequence homology to EGFR, correlated with tumourin cell-cycle control. Loss of Rb function may result in
increased genetic instability and can occur in both grade and survival [69]. Its expression was an indepen-
dent prognosticator in a multivariate analysis. However,noninvasive and invasive bladder tumours, most com-
monly in the latter. Several immunohistochemical stud- conflicting results have been published in a study
reporting no additional prognostic power over tumouries have shown that decreased expression of Rb protein
is associated with more aggressive biological behaviour grade, DNA aneuploidy and proliferative activity
(reviewed in [70]). EGFR overexpression can be used asand a decreased life expectancy [59,60]. A recent study,
evaluating the expression of Rb in bladder tumours from a prognosticator in noninvasive bladder cancer. The
prognostic value of the c-erbB-2 oncoprotein needspatients who had undergone cystectomy, reported that
both cases with undetectable Rb and high Rb expression further evaluation.
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Prognostic significance of morphologic parameters in 121
Angiogenesis cases. Cancer 1988; 61: 1639–51
8 Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G.Bladder cancer is dependent on angiogenesis to grow
Radical nephrectomy for renal cell carcinoma: long-termprogressively and metastasize eBciently [71]. In patients
results and prognostic factors on a series of 328 cases. Eur
with muscle-invasive disease, microvessel density (MVD)
Urol 1997; 31: 40–8
is strongly correlated with lymph node metastases [72], 9 Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S,
disease recurrence and reduced survival [73,74]. Morales P. Renal cell carcinoma: survival and prognostic
However, other investigators found no correlation factors. Urology 1986; 27: 291–301
between prognosis and MVD, but the patient group 10 Ljungberg B, Forsslund G, Stenling R, Zetterberg A.
Prognostic significance of the DNA content in renal cellexamined had a relatively low risk of metastasis [75].
carcinoma. J Urol 1986; 135: 422–6Future studies should provide additional proof of the
11 Murphy WM, Chandler RW, TraCord RM. Flow cytometryutility of MVD as a prognosticator in bladder cancer.
of deparaBnized nuclei compared to histological grading
for the pathological evaluation of transitional cell carci-
nomas. J Urol 1986; 135: 694–7Conclusion
12 Thrasher JB, Paulson DF. Prognostic factors in renal cancer.
The identification of patients with TCC of the bladder at Urol Clin North Am 1993; 20: 247–62
risk of recurrent or progressive cancer at an early stage 13 Citterio G, Bertuzzi A, Tresoldi M et al. Prognostic factors
is important to provide an optimal treatment for these for survival in metastatic renal cell carcinoma: retrospective
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31: 286–91accomplish this and much eCort has been put into
14 Van Poppel H, Vandendriessche H, Boel K et al. Microscopicresearch on such markers. Many potential markers have
vascular invasion is the most relevant prognosticator afterbeen reported; unfortunately, few of them seem to have
radical nephrectomy for clinically nonmetastatic renal cell
true potential prognostic value and their precise clinical
carcinoma. J Urol 1997; 158: 45–9
utility needs to be studied more intensively. Hopefully, 15 Giuliani L, Giberti C, Martorana G, Rovida S. Radical
new clinically valuable prognostic markers may evolve extensive surgery for renal cell carcinoma: long-term
from a better understanding of the molecular events results and prognostic factors. J Urol 1990; 143: 468–73;
involved in bladder cancer progression, leading to the discussion 473–4
16 McNichols DW, Segura JW, DeWeerd JH. Renal cellidentification of patients with potentially recurrent or
carcinoma: long-term survival and late recurrence. J Urolprogressive disease.
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17 Selli C, Hinshaw WM, Woodard BH, Paulson DF.
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pRb expression is associated with bladder cancer pro-
MCQsgression and has cooperative eCects with p53. Cancer Res
1998; 58: 1090–4 1. Which statement is correct?
62 Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. (a) the most important area in TCC tissue marker
Genetic manipulation of E-cadherin expression by epithelial
development would be to predict which superficial
tumour cells reveals an invasion suppressor role. Cell 1991;
tumours are likely to recur and/or to progress66: 107–19
(b) molecular markers have a higher prognostic power63 Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF,
than tumour morphology, stage and grade in predictingDebruyne FM, Schalken JA. Decreased E-cadherin immuno-
tumour progressionreactivity correlates with poor survival in patients with
bladder tumours. Cancer Res 1993; 53: 3241–5 (c) DNA aneuploidy after intravesical treatment of super-
64 Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HA, ficial tumours has good prognostic features in TCC
Bui HX. E-cadherin expression in papillary transitional cell (d) P53 immunohistochemistry is accepted to be
carcinoma of the urinary bladder. Hum Pathol 1995; inversely correlated to prognosis in TCC
26: 940–4 (e) Lack of retinoblastoma tumour suppressor gene
65 Syrigos KN, Krausz T, Waxman J et al. E-cadherin
expression is found in most invasive TCC lesionsexpression in bladder cancer using formalin-fixed, paraBn-
2. Which statement is correct?embedded tissues: correlation with histopathological grade,
(a) the inverse correlation between E-cadherin expressiontumour stage and survival. Int J Cancer 1995; 64: 367–70
and prognosis in TCC may pose practical problems in66 Lipponen PK, Eskelinen MJ. Reduced expression of
E-cadherin is related to invasive disease and frequent standardising the assay for clinical application
recurrence in bladder cancer. J Cancer Res Clin Oncol 1995; (b) epidermal growth factor receptor expression is posi-
121: 303–8 tively correlated with prognosis in patients with muscle-
67 Otto T, Birchmeier W, Schmidt U et al. Inverse relation of invasive TCC
E-cadherin and autocrine motility factor receptor expression (c) microvessel density is an independent prognosticator
as a prognostic factor in patients with bladder carcinomas.
in bladder cancerCancer Res 1994; 54: 3120–3
(d) expression of the C-erbB-2 gene product is a stronger68 Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-
prognosticator than tumour grade, DNA aneuploidy andterm outcome related to epidermal growth factor receptor
proliferative activitystatus in bladder cancer. J Urol 1995; 153: 919–25
69 Sato K, Moriyama M, Mori S et al. An immunohistologic 3. Which statement is correct?
evaluation of C-erbB-2 gene product in patients with (a) tumour grading in bladder carcinoma is not well
urinary bladder carcinoma. Cancer 1992; 70: 2493–8 suited for predicting progression to muscle invasion
70 Vet JA, Debruyne FM, Schalken JA. Molecular prognostic (b) determination of DNA ploidy in muscle-invasive
factors in bladder cancer. World J Urol 1994; 12: 84–8 bladder carcinoma reflects the true metastatic potential
71 Campbell SC. Advances in angiogenesis research: relevance
(c) patients with p53-positive nuclear staining have ato urological oncology. J Urol 1997; 158: 1663–74
significantly shorter disease-free interval in T1 bladder72 Jaeger TM, Weidner N, Chew K et al. Tumour angiogenesis
cancercorrelates with lymph node metastases in invasive bladder
(d) tumour heterogeneity does not influence the predic-cancer. J Urol 1995; 154: 69–71
73 Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in tive value of flow cytometry in bladder carcinoma
bladder cancer: relationship between microvessel density 4. Which statement is correct?
and tumour prognosis. J Natl Cancer Inst 1995; 87: (a) expression of retinoblastoma tumour suppressor gene
1603–12 in TCC of the bladder correlates well with aggressive
74 Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, biological behaviour and decreased life expectancy
Harris AL. Quantification of angiogenesis as an independent
(b) E-cadherin expression in bladder carcinoma is not anpredictor of prognosis in invasive bladder carcinomas. Br
independent prognostic factor over grade and stageJ Urol 1994; 74: 762–6
(c) gp 78, an autocrine motility factor receptor, has75 Babkowski R, Zhang H-Z, Xia Y et al. Angioneogenesis
independent prognostic value in bladder carcinomadoes not have prognostic value in T1 bladder cancer. J Urol
1996; 156: 615A (d) invasive bladder carcinoma is associated with a low
frequency of p53 mutations
5. Which statement is correct?Authors
(a) cytogenetic abnormalities have been shown to be the
J.P. van Brussel, M.D., President in Urology.
strongest prognosticators in RCCG.H.J. Mickisch, M.D., PhD, Professor of Urology.
(b) the expression of chemoresistance genes in RCC hasCorrespondence: Professor Dr G.H.J. Mickisch, Department of
a negative prognostic valueUrology, Academic Hospital Rotterdam, H1095, Dr
(c) overall, the TNM staging system is the most widelyMolenwaterplein 40, NL 3015 GD Rotterdam, The Netherlands.
E-mail: Mickisch@urol.azr.nL used prognosticator in clinical decision-making for RCC
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(d) renal capsular invasion and perinephric fat invasion up after curative surgery for RCC includes measuring
the haemoglobin level, ESR and alkaline phosphataseindicates a worse prognosis than microscopic vascular
(b) RCC, apart from testicular cancer, has a good prog-invasion in RCC
nosis compared with other urological malignancies6. Which statement is correct?
(c) prognostic factors have established value in the(a) grading, nuclear morphometry and DNA content are
optimal treatment for metastatic RCCwell established prognosticators in clinical decision-
(d) tumour penetration of RCC into the renal pelvis ismaking for RCC
thought to be an independent prognosticator(b) allelic losses of 17p have prognostic value in clear
9. Which statement is correct?cell carcinoma
(a) Surgical tumour debulking improves response rates(c) the age at diagnosis is an important prognosticator
under immunotherapy for metastatic RCCin RCC
(b) Resection of metastasis improves overall survival in(d) microvascular invasion is of prognostic significance
stage M+RCC
in organ-confined RCC
(c) The tumour cell type does not influence the prognosis
7. Which statement is correct?
of RCC
(a) deletions in the short arm of chromosome 3 are (d) Anaemia at diagnosis may predict a poor outcome
common in papillary RCC of metastatic RCC
(b) female patients with RCC may show elevated PSA 10. Which statement is correct?
levels in 22–25% of cases (a) overall, men with RCC have a poorer prognosis than
(c) when compared with each other, venous micro- women with RCC
invasion conveys a better prognosis than a large tumour (b) oncocytomas commonly have deletions in the Y
volume in RCC chromosome
(d) hereditary forms of RCC carry a worse prognosis (c) RCCs are commonly seen from age 20 to age 85
than sporadic cases years with a peak incidence in the fourth decade
8. Which statement is correct? (d) nuclear morphometry is established in the clinical
decision-making for RCC(a) the recommended laboratory evaluation in the follow-
© 1999 BJU International 83, 902–909
